• Open Access

Efficacy of AST-120 in Dogs with Chronic Idiopathic Enteropathies

Authors


  • Parts of this paper were presented as an abstract at the 2012 ACVIM Forum, New Orleans and the Postgraduates' Symposium of the Faculty of Veterinary Medicine, Freie Universitaet Berlin, Germany, 2012.

Abstract

Background

Chronic idiopathic enteropathies (CIE) in dogs are complex diseases of unknown origin. AST-120 is a spherical carbon adsorbent preparation with a high adsorption ability for low molecular substances.

Objectives

Evaluation of the clinical efficacy of AST-120 in dogs with CIE.

Animals

Ten client-owned dogs with mild (n = 7) to moderate (n = 3) CIE.

Methods

Explorative, prospective, randomized, placebo-controlled, double-blinded pilot study. Dogs with chronic diarrhea and no or insufficient response to an elimination diet were included. The dogs received either AST-120 (n = 5) or placebo (n = 5) for a duration of 21 days. The canine inflammatory bowel disease activity index (CIBDAI) was used to assess disease severity at baseline and clinical outcome after 3 weeks of treatment. Furthermore, changes in body weight and the parameters stool consistency and frequency were compared within and between groups.

Results

The mean CIBDAI score decreased from 5.6 (SD 1.5) to 2.0 (SD 1.2) in the AST-120 group (P = .125) and from 4.8 (SD .8) to 3.6 (SD 2.3) in the placebo group (P = .688). Compared with baseline, posttreatment CIBDAI scores decreased more than 60% in 4/5 dogs treated with AST-120 and in 1/5 dogs treated with placebo (P = .206). Changes in CIBDAI scores, body weights, stool consistency, and frequency within and between groups did not achieve statistical significance after 3 weeks of treatment. No adverse effects of AST-120 were noted.

Conclusions and Clinical Importance

This study investigated potential efficacy of AST-120 as an alternative therapy in dogs with mild-to-moderate CIE.

Ancillary